Home / Health / Lilly's Oral GLP-1 Pill Delivers 12% Weight Loss in Obesity Trial
Lilly's Oral GLP-1 Pill Delivers 12% Weight Loss in Obesity Trial
7 Aug
Summary
- Lilly's experimental oral GLP-1 medication helped people lose an average of 12% of their body weight
- The pill reduced weight by 27.3 pounds (12.4%) in participants with obesity or overweight and at least one weight-related medical problem
- 59.6% of participants on the highest dose lost at least 10% of their body weight
According to a news release from Eli Lilly, the company's experimental once-daily oral GLP-1 medication has shown promising results in a recent Phase 3 trial for the treatment of obesity. The study, which involved more than 3,127 adults, found that the pill, called orforglipron, helped participants lower their weight by an average of 12% after 72 weeks.
Specifically, the data revealed that participants who had obesity or overweight with at least one weight-related medical problem, and who were not diabetic, lost an average of 27.3 pounds (12.4%) when taking the highest dose of the medication. Additionally, 59.6% of those on the highest dose lost at least 10% of their body weight, and 39.6% lost at least 15%.
The oral GLP-1 pill was also associated with lower markers of cardiovascular risk, including improved cholesterol and blood pressure levels. While the side effects were similar to those seen with Lilly's injectable GLP-1 drugs, the company noted that the percentage of participants experiencing gastrointestinal issues, such as nausea, constipation, and diarrhea, was slightly higher.
Lilly is now planning to submit orforglipron for regulatory review by the end of this year, with the goal of making the medication available to address the urgent public health need for effective obesity treatments.
